WOIPPY, France--(BUSINESS WIRE)--July 02, 2026-- 

Regulatory News:

At the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a dividend of EUR0.11 per share for the 2025 fiscal year (compared with EUR0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position.

The dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026.

About ABL Diagnostics $(ABLD)$

ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:

   --  Molecular polymerase chain reaction $(PCR)$ detection -- UltraGene, and 
 
 
   --  Genotyping by DNA sequencing -- DeepChek$(R)$. 

ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:

   --  HIV -- Drug resistance testing, including a whole genome kit. 
 
   --  SARS-CoV-2, Tuberculosis, Hepatitis B and C -- Advanced Detection 
      Solutions. 
 
   --  Microbiome and taxonomy -- 16s/18s RNA-based analyses. 
 
   --  Other viral and bacterial targets -- Comprehensive molecular assays. 

Integrated Solutions

   --  Real-time syndromic PCR tests 
 
   --  Nadis(R) -- Patient Medical Record used in more than 200 hospitals in 
      France for the management of HIV and hepatitis. 
 
   --  MediaChek(R) -- Clinical Sample Collection Kits. 

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD -- ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260702954947/en/

 
    CONTACT:    ABL Diagnostics SA 

Société anonyme au capital de 1 611 465,60 euros

Headquarters : 72C route de Thionville - 57140 WOIPPY

552 064 933 R.C.S. METZ

Tel : +33 (0)7 83 64 68 50

Email : info@abldiagnostics.com

https://www.abldiagnostics.com/

(END) Dow Jones Newswires

July 02, 2026 12:00 ET